$11.59
+0.21
(+1.8%)▲
Live
Revenue is down for the last 2 quarters, 2.84M → 2.04M (in $), with an average decrease of 28.0% per quarter
Netprofit is down for the last 2 quarters, -16.06M → -17.45M (in $), with an average decrease of 8.7% per quarter
In the last 1 year, Seagen Inc has given 36.8% return, outperforming this stock by 39.7%
2.93%
Downside
Day's Volatility :3.35%
Upside
0.43%
18.9%
Downside
52 Weeks Volatility :60.24%
Upside
50.97%
Period | JANUX THERAPEUTICS INC | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -31.54% | 0.3% | -6.7% |
6 Months | -16.53% | -8.3% | -6.2% |
1 Year | 2.29% | -4.8% | -6.3% |
3 Years | -59.03% | 23.8% | 26.9% |
Market Capitalization | 476.3M |
Book Value | $7.45 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -1.44 |
Wall Street Target Price | 27.5 |
Profit Margin | 0.0% |
Operating Margin TTM | -813.91% |
Return On Assets TTM | -12.79% |
Return On Equity TTM | -20.11% |
Revenue TTM | 9.1M |
Revenue Per Share TTM | 0.22 |
Quarterly Revenue Growth YOY | 28.9% |
Gross Profit TTM | -44.8M |
EBITDA | -72.6M |
Diluted Eps TTM | -1.44 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.99 |
EPS Estimate Next Year | -2.48 |
EPS Estimate Current Quarter | -0.49 |
EPS Estimate Next Quarter | -0.52 |
What analysts predicted
Upside of 137.27%
Sell
Neutral
Buy
JANUX THERAPEUTICS INC is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() JANUX THERAPEUTICS INC | -25.83% | -16.53% | 2.29% | -59.03% | -59.03% |
![]() Moderna, Inc. | -5.37% | -28.24% | -13.14% | 103.02% | 578.71% |
![]() Regeneron Pharmaceuticals, Inc. | -10.12% | -3.55% | 9.07% | 20.95% | 140.97% |
![]() Seagen, Inc. | -2.85% | 59.4% | 42.61% | 21.68% | 240.77% |
![]() Vertex Pharmaceuticals Incorporated | -4.35% | 4.3% | 22.83% | 15.12% | 110.67% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() JANUX THERAPEUTICS INC | NA | NA | NA | -1.99 | -0.2 | -0.13 | 0.0 | 7.45 |
![]() Moderna, Inc. | 11.22 | 11.22 | 0.0 | -1.83 | 0.27 | 0.12 | 0.0 | 49.12 |
![]() Regeneron Pharmaceuticals, Inc. | 19.72 | 19.72 | 9.01 | 41.59 | 0.19 | 0.1 | 0.0 | 219.38 |
![]() Seagen, Inc. | NA | NA | 18.53 | -2.88 | -0.23 | -0.12 | 0.0 | 14.54 |
![]() Vertex Pharmaceuticals Incorporated | 26.53 | 26.53 | 0.41 | 13.64 | 0.26 | 0.17 | 0.0 | 56.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() JANUX THERAPEUTICS INC | Buy | $476.3M | -59.03% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $48.1B | 578.71% | 11.22 | 31.77% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $79.5B | 140.97% | 19.72 | 33.81% |
![]() Seagen, Inc. | Hold | $36.3B | 240.77% | NA | -31.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $85.0B | 110.67% | 26.53 | 35.4% |
RA Capital Management, LLC
FMR Inc
EcoR1 Capital, LLC
Orbimed Advisors, LLC
HHG PLC
Citadel Advisors Llc
JANUX THERAPEUTICS INC’s price-to-earnings ratio stands at None
Read MoreJanux Therapeutics is developing safe, effective novel immunotherapies with the company’s proprietary TRACTr technology. Janux’s TRACTr technology employs a modular design to rapidly engineer drug candidates against specific targets. The Janux TRACTr development pipeline targets multiple solid tumor indications, including colorectal, gastroesophageal, prostrate, NSCLC, triple negative breast, and ovarian cancers. Janux technology can be applied to immunotherapies that target all three stages of an anti-tumor immune response. Combining Janux’s tumor-specific activation with multi-stage anti-tumor signaling has the potential to significantly improve safety, expand the therapeutic dosing window, and maximize patient responses. Janux was founded in the Avalon Ventures accelerator, COI Pharmaceuticals, Inc., in San Diego.
Organization | JANUX THERAPEUTICS INC |
Employees | 62 |
CEO | Dr. David Alan Campbell Ph.D. |
Industry | Healthcare |
First Majestic Silver Corp
$5.72
-0.52%
ONYX ACQUISITION CO. I
$10.49
-4.64%
Diversified Healthcare Trust
$1.17
+2.63%
ALTC ACQUISITION CORP-CL A
$10.71
+0.56%
iShares Morningstar Value ETF
$63.30
-0.17%
Nationwide Nasdaq-100 Risk-Managed Income ETF
$20.52
+0.2%
ENFUSION INC
$7.73
-1.9%
WisdomTree Trust - WisdomTree International Quality Dividend Growth Fund
$33.67
-0.56%
GIGACLOUD TECHNOLOGY INC
$6.75
+4.65%